[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-381848-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-381848-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","genitourinary-cancers-updates-highlights-from-asco-2023","Genitourinary cancers updates - highlights from ASCO 2023","","Significant scientific advances in immunotherapy and targeted therapy have improved clinical outcomes and expanded treatment options for patients with genitourinary (GU) malignancies. The article highlights key clinical trial developments from the ASCO 2023 annual meeting, including PARP inhibitors for prostate cancer, antibody drug conjugates and FGFR inhibitors for urothelial cancer, and HIF2α inhibitors for renal cell carcinoma. It also reviews early-phase innovations such as bispecific antibodies, CAR T-cells, and radiopharmaceuticals, and emphasizes the need to define optimal treatment sequencing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/genitourinary-cancers-updates-highlights-from-asco-2023/381848/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/genitourinary-cancers-updates-highlights-from-asco-2023/381848.png","ImageObject",300,407,{"name":42,"@type":43},"Franzy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which GU cancer areas are covered in the ASCO 2023 highlights?","Question",{"text":63,"@type":64},"The updates focus on prostate cancer, urothelial cancer, and renal cell carcinoma, summarizing major therapeutic developments reported at ASCO 2023.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What treatment categories are highlighted for prostate cancer?",{"text":68,"@type":64},"The article highlights PARP inhibitors, immunotherapy approaches, bispecific antibodies, CAR T-cells, and PSMA-directed radionuclide therapy, alongside late-breaking data from key phase 3 trials.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is treatment sequencing emphasized for GU cancers?",{"text":72,"@type":64},"Because more effective treatment options are emerging, the field must define best sequencing strategies to optimize outcomes for each patient.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},381848,1790613766,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Qin et al. Journal of Hematology & Oncology (2023) 16:112 [https://doi.org/10.1186/s13045-023-01511-8](https://doi.org/10.1186/s13045-023-01511-8)  \nJournal of Hematology & Oncology  \n EDITORIAL Open Access  \nGenitourinary cancers updates: highlights from ASCO 2023  \nQian Qin1, Hollie Sheffield1, Sean M. Taasan 1, Andrew Z. Wang2 and Tian Zhang1*  \nAbstract  \nSignificant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomesand increased treatment options for patients with genitourinary (GU) malignancies. We highlight the clinical trial developments released at the ASCO 2023 annual meeting, including PARP inhibitors for prostate cancer, antibody drug conjugates and fibroblast growth factor receptor inhibitors for urothelial cancer, and HIF2a inhibitors for renal cell carcinoma. Novel agents such as bispecific antibodies, chimeric antigen receptor T-cells, and radiopharmaceuticals are currently in early phase development and also have high potential impact for the GU cancer landscape. With more treatment options, the field will need to define best treatment sequencing to optimize outcomes for each patient.  \nIntroduction  \nTherapeutic advances in genitourinary (GU) malignancies have progressed rapidly. Prostate cancer has seen multiple combination treatments in upfront metastatic hormone sensitive disease, as well as the addition of PARP inhibitors for castration resistant prostate cancer with homologous recombination repair defects. Inurothelial cancer, the advent of antibody drug conjugates and fibroblast growth factor receptor inhibitors have added multiple therapeutic options in the advanced setting, and many are under investigation in the localized setting. In kidney cancer, combination regimens of immune checkpoint inhibitor (IO) with or without vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) have become standard of care, and novel agents such as HIF2a inhibitors hold much  \n*Correspondence:  \nTian Zhang [tian.zhang@utsouthwestern.edu](tian.zhang@utsouthwestern.edu)  \n1 Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA  \n2 Department of Radiation Oncology, UT Southwestern Medical Center, Dallas 75235, USA  \npromise. We summarize recent therapeutic updates in GU cancers at the ASCO 2023 annual meeting.  \nProstate  \nSeveral trials highlighting novel treatments under investigation (including PSMA-directed radionuclide therapy, PARP inhibitors, immunotherapy, bispecific antibodies, and CAR T-cells) were featured (Table 1). In addition, further data from two previously published major phase 3 trials (PEACE-1, TALAPRO-2) with potentially practice-changing implications were presented [1, 2].  \nLate-breaking data from PEACE-1 evaluating the impact of radiotherapy in first-line patients with de novo metastatic castration sensitive prostate cancer (mCSPC) showed a statistically significant increase in the coprimary endpoint of rPFS in patients with low-volume mCSPC who received standard of care (SOC) + abiraterone + radiotherapy compared to SOC +abiraterone (median 7.5 versus 4.4 years, p = 0.02) [15]. There was no statistically significant rPFS benefit when radiotherapy was added to SOC alone. The co-primary endpoint of overall survival (OS) was not statistically significantly improved between the cohorts, although it is difficult to show an OS improvement in this patient population. Secondary endpoints of castration resistance-free survival  \n© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are","cbCaivvMRFcezcbG","https://ap.wps.com/l/cbCaivvMRFcezcbG","pdf",876328,"English","# Introduction\n# Prostate\n## Table 1: Novel regimens under investigation—prostate cancer highlights from ASCO 2023","[{\"question\":\"Which GU cancer areas are covered in the ASCO 2023 highlights?\",\"answer\":\"The updates focus on prostate cancer, urothelial cancer, and renal cell carcinoma, summarizing major therapeutic developments reported at ASCO 2023.\"},{\"question\":\"What treatment categories are highlighted for prostate cancer?\",\"answer\":\"The article highlights PARP inhibitors, immunotherapy approaches, bispecific antibodies, CAR T-cells, and PSMA-directed radionuclide therapy, alongside late-breaking data from key phase 3 trials.\"},{\"question\":\"Why is treatment sequencing emphasized for GU cancers?\",\"answer\":\"Because more effective treatment options are emerging, the field must define best sequencing strategies to optimize outcomes for each patient.\"}]","Genitourinary cancers updates - highlights from ASCO 2023 | PDF",1790247448]